Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repligen v. Centocor

Executive Summary

Repligen settles April 3 lawsuit in exchange for a share of any profits derived from the sale of a potential monoclonal antibody HIV treatment now under development by Centocor. Announced June 9, the settlement allows Centocor to continue work on its F105 antibody while acknowledging a 1987 non-compete agreement with Repligen covering HIV therapeutics, vaccines and diagnostics. That agreement gave Repligen all rights to an AIDS vaccine to which, under an earlier joint venture, Centocor had marketing rights.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel